If the role of ITPKB as risk factor for PD will be further confirmed, inhibition of this kinase activity may offer alternative therapeutical approaches for PD patients, especially those in which SNCA multiplication or A53T/A30P have been identified. Here, ITPKB is linked to Parkinson disease.